Logo
Sponsored by:
Presented by:

High sensitivity measurement of immunogenicity is important for patient safety

Impacting patient safety with high sensitivity ADA detection

Available On Demand

This webcast has been produced for the sponsor, Merck KGaA Darmstadt , Germany, who retains sole responsibility for content. 

Your details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)

  Register

Overview

High sensitivity measurement of immunogenicity is important for patient safety

Impacting patient safety with high sensitivity ADA detection

Available On Demand

If you've already registered, please click here to log in to the webcast

Drug immunogenicity and the detection of anti-drug antibodies (ADA) have an important role in the drug discovery process for potential new therapeutics. The clinical effects of these immune responses can affect pharmacokinetics, pharmacodynamics, safety, or efficacy. Detection and analysis of ADA formation is crucial for any therapeutic protein product development program.

Current requirements for screening and confirmatory IgG ADA assays aim to achieve a sensitivity of at least 100 nanograms per millilitre (ng/mL). However, at this sensitivity the primary response to antigen exposure, and resultant pentameric IgM generation, may be missed while IgE ADA may also elude the assay due to its low concentration.

A high sensitivity detection platform would therefore be advantageous in order to detect ADA sooner and at much lower concentrations than the current requirements, thus leading to improved drug safety. Improved sensitivity and dynamic range could also potentially be used to overcome some of the challenges, such as matrix and drug tolerance, that traditional assays exhibit. This presentation aims to show how Single Molecule Counting technology can assist in improving assay sensitivity and therefore therefore improve drug safety.

In this webcast, you will learn about:

  • How a high sensitivity ADA immunogenicity assay can help with drug safety.
  • How you can overcome the challenges of matrix interference and drug tolerance using a high sensitivity platform.
  • How a high sensitivity assay can help you overcome current technology limitations.
This webcast has been produced for Merck KGaA, Darmstadt, Germany by Nature Research Custom Media. The sponsor retains sole responsibility for content.  About this content.

Presenters

Presenter
Daniel Garcia-West
Field Marketing Manager
Merck KGaA, Darmstadt, Germany
View Biography
Presenter
Moderator: Sarah Hiddleston
Journalist
Nature Middle East
View Biography